Abstract B044: Fragmentomic features of cell-free DNA predict late-stage melanoma treatment benefit and survival
Aaron B. Beasley, Elin S. Gray(Edith Cowan University), Wei Yen Chan(Melanoma Institute Australia), Peter K. H. Lau(Sir Charles Gairdner Hospital), Leslie Calapre(Edith Cowan University), Helen Rizos(Macquarie University), Russell J. Diefenbach(The University of Sydney), Georgina V. Long(The University of Sydney), Tarek Meniawy(St John of God Subiaco Hospital), Michael Millward(The University of Western Australia), Ashleigh Stewart(The University of Sydney), Richard A. Scolyer(The University of Sydney), Lydia Warburton(Edith Cowan University), Jenny Lee(Blacktown & Mount Druitt Hospital), Muhammad A. Khattak, Rebecca Auzins(Edith Cowan University), Alexander M. Menzies(The University of Sydney), Luisa Pinnel(Edith Cowan University), Anna Reid(Edith Cowan University)
Cited by 0
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2012|906